285 related articles for article (PubMed ID: 15060793)
1. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost.
Chiba T; Kashiwagi K; Ishijima K; Furuichi M; Kogure S; Abe K; Chiba N; Tsukahara S
Jpn J Ophthalmol; 2004; 48(2):141-7. PubMed ID: 15060793
[TBL] [Abstract][Full Text] [Related]
2. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.
Chou SY; Chou CK; Kuang TM; Hsu WM
Eye (Lond); 2005 Jul; 19(7):784-7. PubMed ID: 15359238
[TBL] [Abstract][Full Text] [Related]
3. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.
Chiba T; Kashiwagi K; Kogure S; Abe K; Shibuya T; Furuichi M; Iijima H; Tsukahara S
J Glaucoma; 2001 Oct; 10(5):406-10. PubMed ID: 11711839
[TBL] [Abstract][Full Text] [Related]
4. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study.
Chiba T; Kashiwagi K; Chiba N; Ishijima K; Furuichi M; Kogure S; Abe K; Tsukahara S
Br J Ophthalmol; 2003 Aug; 87(8):956-9. PubMed ID: 12881333
[TBL] [Abstract][Full Text] [Related]
5. Assessment of chamber angle pigmentation during longterm latanoprost treatment for open-angle glaucoma.
Nakamura Y; Nakamura Y; Morine-Shinjo S; Sakai H; Sawaguchi S
Acta Ophthalmol Scand; 2004 Apr; 82(2):158-60. PubMed ID: 15043533
[TBL] [Abstract][Full Text] [Related]
6. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension.
Alm A; Grunden JW; Kwok KK
J Glaucoma; 2011; 20(4):215-22. PubMed ID: 20520568
[TBL] [Abstract][Full Text] [Related]
7. Latanoprost and pigmentation.
Grierson I; Jonsson M; Cracknell K
Jpn J Ophthalmol; 2004; 48(6):602-12. PubMed ID: 15592791
[TBL] [Abstract][Full Text] [Related]
8. Analysis of irises with a latanoprost-induced change in iris color.
Arranz-Marquez E; Teus MA; Saornil MA; Mendez MC; Gil R
Am J Ophthalmol; 2004 Oct; 138(4):625-30. PubMed ID: 15488791
[TBL] [Abstract][Full Text] [Related]
9. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
McCarey BE; Kapik BM; Kane FE;
Ophthalmology; 2004 Aug; 111(8):1480-8. PubMed ID: 15288975
[TBL] [Abstract][Full Text] [Related]
10. [Adverse reaction after use of latanoprost in Japanese glaucoma patients].
Inoue K; Wakakura M; Inoue J; Matsuo H; Hara T; Tomita G
Nippon Ganka Gakkai Zasshi; 2006 Aug; 110(8):581-7. PubMed ID: 16972649
[TBL] [Abstract][Full Text] [Related]
11. Effect of age on the development of a latanoprost-induced increase in iris pigmentation.
Arranz-Marquez E; Teus MA
Ophthalmology; 2007 Jul; 114(7):1255-8. PubMed ID: 17306877
[TBL] [Abstract][Full Text] [Related]
12. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.
Wistrand PJ; Stjernschantz J; Olsson K
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S129-38. PubMed ID: 9154289
[TBL] [Abstract][Full Text] [Related]
13. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy.
Sharpe ED; Reynolds AC; Skuta GL; Jenkins JN; Stewart WC
Curr Eye Res; 2007 Dec; 32(12):1037-43. PubMed ID: 18085467
[TBL] [Abstract][Full Text] [Related]
14. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma.
Alm A; Schoenfelder J; McDermott J
Arch Ophthalmol; 2004 Jul; 122(7):957-65. PubMed ID: 15249358
[TBL] [Abstract][Full Text] [Related]
15. Morphometric effects of long-term exposure to latanoprost.
Cracknell KP; Grierson I; Hogg P
Ophthalmology; 2007 May; 114(5):938-48. PubMed ID: 17292473
[TBL] [Abstract][Full Text] [Related]
16. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes.
Latanoprost-Induced Iris Pigmentation Study Group
Jpn J Ophthalmol; 2006; 50(2):96-9. PubMed ID: 16604382
[TBL] [Abstract][Full Text] [Related]
17. Increased iridial pigmentation in Chinese eyes after use of travoprost 0.004%.
Huang P; Zhong Z; Wu L; Liu W
J Glaucoma; 2009 Feb; 18(2):153-6. PubMed ID: 19225354
[TBL] [Abstract][Full Text] [Related]
18. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G
Am J Ophthalmol; 2006 Dec; 142(6):1059-60. PubMed ID: 17157592
[TBL] [Abstract][Full Text] [Related]
19. Adverse periocular reactions to five types of prostaglandin analogs.
Inoue K; Shiokawa M; Higa R; Sugahara M; Soga T; Wakakura M; Tomita G
Eye (Lond); 2012 Nov; 26(11):1465-72. PubMed ID: 23037910
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
Chiseliţă D; Antohi I; Medvichi R; Danielescu C
Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
